# Combination of Capecitabine and Oxaliplatin in Patients With Relapsed or Refractory Gastric Cancer

> **NCT00568529** · PHASE2 · SUSPENDED · sponsor: **Fudan University** · enrollment: 30 (estimated)

## Conditions studied

- Gastric Cancer

## Interventions

- **DRUG:** Capecitabine and Oxaliplatin

## Key facts

- **NCT ID:** NCT00568529
- **Lead sponsor:** Fudan University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** SUSPENDED
- **Start date:** 2007-10
- **Primary completion:** 2009-06
- **Final completion:** 2010-02
- **Target enrollment:** 30 (ESTIMATED)
- **Why stopped:** There are not enough patients enrolled.
- **Last updated:** 2010-05-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00568529

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00568529, "Combination of Capecitabine and Oxaliplatin in Patients With Relapsed or Refractory Gastric Cancer". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT00568529. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*